{"commentary":{"count":129,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":65,"youtube":36,"podcast":23,"x_video":5},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05152147\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"HERIZON-GEA-01","nct_id":"NCT05152147","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=herizon-gea-01-nct05152147. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"HERIZON-GEA-01","arms":[{"description":"Trastuzumab (Herceptin®) plus physician's choice of capecitabine plus oxaliplatin (CAPOX) or 5-fluorouracil (5-FU) plus cisplatin (FP)","label":"Arm A","type":"ACTIVE_COMPARATOR"},{"description":"Zanidatamab plus physician's choice of CAPOX or FP","label":"Arm B","type":"EXPERIMENTAL"},{"description":"Zanidatamab and tislelizumab plus physician's choice of CAPOX or FP","label":"Arm C","type":"EXPERIMENTAL"}],"collaborators":["BeOne Medicines LTD","BeOne Pharmaceutical Co., Ltd."],"completion_date":{"date":"2027-09-30","type":"ESTIMATED"},"conditions":["Gastric Neoplasms","Gastroesophageal Adenocarcinoma","Esophageal Adenocarcinoma"],"enrollment":{"count":920,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Zanidatamab","type":"DRUG"},{"name":"Tislelizumab","type":"DRUG"},{"name":"Trastuzumab","type":"DRUG"},{"name":"Capecitabine","type":"DRUG"},{"name":"Oxaliplatin","type":"DRUG"},{"name":"Cisplatin","type":"DRUG"},{"name":"5-Fluorouracil","type":"DRUG"}],"last_update":"2026-09-24","lead_sponsor":"Jazz Pharmaceuticals","official_title":"A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination With Chemotherapy With or Without Tislelizumab in Subjects With HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-07-15","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-free survival (PFS) by BICR","timeFrame":"Up to 2.5 years"},{"measure":"Overall survival","timeFrame":"Up to 3.5 years"}],"references":[{"citation":"Shitara K, Elimova E, Liu T, Tabernero J, Lee KW, Schenker M, Tebbutt NC, Ajani J, Salimin N, Ku G, Gwang Kim J, Ales Diaz I, Zhang J, Pietrantonio F, Bai LY, Le Sourd S, Zhao J, Hierro C, Kiberu A, Van Herpe F, Bao Y, Zhang H, Yang L, Li V, Gartner EM, Chen Y, Grim J, Rha SY, Shen L; HERIZON-GEA-01 Investigators. Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer. N Engl J Med. 2026 May 28;394(20):2002-2014. doi: 10.1056/NEJMoa2517729.","pmid":"42202319","type":"DERIVED"},{"citation":"Lee KW, Bai LY, Jung M, Ying J, Im YH, Oh DY, Cho JY, Oh SC, Chao Y, Kim JW, Chen Y, Li V, Chen S, Kang YK. Phase Ib/II Study of Zanidatamab in Combination with Tislelizumab and Chemotherapy in First-Line HER2-Positive Gastric/Gastroesophageal Junction Adenocarcinoma. Clin Cancer Res. 2026 Jan 16;32(2):312-323. doi: 10.1158/1078-0432.CCR-24-4295.","pmid":"41324998","type":"DERIVED"},{"citation":"Yu J, Mehta R. Biomarker-Driven Approach to the Treatment of Metastatic Gastric or Gastroesophageal Adenocarcinoma. J Natl Compr Canc Netw. 2025 May;23(5):e257036. doi: 10.6004/jnccn.2025.7036.","pmid":"40341124","type":"DERIVED"},{"citation":"Tabernero J, Shen L, Elimova E, Ku G, Liu T, Shitara K, Lin X, Boyken L, Li H, Grim J, Ajani J. HERIZON-GEA-01: Zanidatamab + chemo +/- tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma. Future Oncol. 2022 Sep;18(29):3255-3266. doi: 10.2217/fon-2022-0595. Epub 2022 Aug 24.","pmid":"36000541","type":"DERIVED"}],"start_date":{"date":"2021-12-02","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers","url":"https://clinicaltrials.gov/study/NCT05152147"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/herizon-gea-01-nct05152147"}